From IPO to M&A: 3 recent tales of Bay Area biotech ups and downs

Is the biotech bubble blowing up in the faces of a few Bay Area life sciences companies? It depends on how you look at a trio of companies' recent news. After a 2014-15 run that minted 32 public companies regionally and raised close to $3 billion, three of those IPO companies this week showed that it's not all happy days. Revance Therapeutics shifted gears after its topical version of Botox failed a late-stage study, Corium International Inc. will lay off 17 percent of its workforce to zero in on…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news